Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for APREPITANT
- Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
- The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting
- Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC
- Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery
- Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents
- The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.
- Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
- Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
- Efficacy and Safety of High Dose Aprepitant Treatment in Patients With Advanced Non-Small Cell Lung Cancer
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
- Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
- Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
- To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients
- Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy
- Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation
- Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting
- Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy
- Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
- Phase 2 Bunionectomy HTX-011 Administration Study
- Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
- Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy
- SIMPLE Chemotherapy for NK Lymphoma/Leukaemia
- PALONOSETRON X FOSAPREPITANT IN PONV
- Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
- Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
- Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma
- Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
- Low Dose Aprepitant for Patients Receiving Carboplatin
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying
- Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy
- Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
- Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
- Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
- Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study
- Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
- Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
- A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
- Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
- Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy
- Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
- Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries
- Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
- Prospective, Double Blind, Placebo Control, Bariatric IV Ace
- Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
- Palonosetron Associated to Aprepitant in Prophylaxis of PONV
- Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
- A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
- Neurokinin Receptor Antagonist Associated to Ondansetron in PONV
- Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)
- Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
- Aprepitant to Mitigate Opioids' Cognitive Side Effects
- Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
- Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients
- Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
- Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects
- Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
- Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
- Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
- A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
- Prevention of Nausea and Vomiting in Patients After Surgery
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Topical Aprepitant in Prurigo Patients
- The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting
- Differentiating the Effects of Substance P and Beta-endorphin
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
- Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
- A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)
- Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
- Aprepitant in the Management of Biological Therapies-related Severe Pruritus
- Efficacy of Aprepitant (Emend®) in Children
- Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
- A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclopho
- Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
- Treatment for Cannabis Withdrawal and Dependence
- Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting
- The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing
- Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
- Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
- Aprepitant Effects in Intravenous Heroin Dependence
- Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
- Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
- Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy
- Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
- Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
- Developing Individualized Strategies to Prevent Nausea and Vomiting
- A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
- Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
- Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
- Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
- Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
- Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
- Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
- Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
- Medications Development for the Treatment of Cannabis Related Disorders
- Comparison of Adding EMEND to PONV/PDNV Treatment Regimen
- Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study
- HBPL Study of the Impact of the NK1 Antagonist Aprepitant
- Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
- Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis
- Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
- Treatment of Chemotherapy-induced Nausea and Vomiting
- Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting
- Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
- Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer
- TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
- Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer
- Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
- Aprepitant for Post-operative Nausea
- Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer
- Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
- Aprepitant Effects on Oxycodone Response
- A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
- Effects of Substance P Antagonists on Adrenal Secretion
- Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy
- Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients
- Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
- Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
- A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
- The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD
- Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy
- Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
- Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
- Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
- Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries
- A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
- A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
- Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
- Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea
- Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients
- A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
- Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
- Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers
- Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
- Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
- Emend for Multiple-day Emetogenic Chemotherapy
- Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting
- Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery
- Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
- Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
- Multi-day Doses in Prevention of Nausea and Emesis
- Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
- Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
- Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy
- Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
- Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
- Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)
- Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals
- AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
- Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
- Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
- Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
- Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
- Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting
- Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
- Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
- Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
- An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
- 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
- Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
- 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
- Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)
- Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
Clinical trials list
click for details